


Korean CDMO ST Pharm accelerates manufacturing of RNA-based vaccines therapeutics with Quantoom Biosciences

20 August 2024 | News

Delivering cutting-edge solutions that drive innovation in the mRNA therapeutics space



ST Pharm, a leading technology-driven RNA CDMO based in South Korea, and Belgium-based Quantoom Biosciences, a specialised RNA technology platform developer, have announced an extended collaboration to accelerate the development and manufacturing of RNA-based vaccines and therapeutics.

This collaboration brings together complementary expertise to enhance the global supply of critical RNA manufacturing technologies, with a first supply agreement of ST Pharm's proprietary 5'-capping reagent, SmartCap.

By combining their respective strengths and expertise, ST Pharm and Quantoom aim to expand their global reach and provide comprehensive solutions to the RNA manufacturing market. This partnership will enable both companies to leverage their technologies more effectively, accelerating the development and production of innovative RNA-based therapies.

This initial collaboration paves the road to an extended partnership in which ST Pharm's proprietary and advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents, will be made available with Quantoom's Ntensify and Ncapsulate mRNA production platform, with the aim to create a more robust and flexible RNA manufacturing ecosystem.

As a CDMO, ST Pharm will gain valuable insights into Quantoom's Ntensify mRNA production processes, while Quantoom will benefit from the expanded capabilities enabled by ST Pharm's unique technologies which will result in unprecedented levels of manufacturing flexibility for its customers.